{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:40:08Z","timestamp":1751578808348,"version":"3.41.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.rgmx.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T17:16:19Z","timestamp":1524417379000},"page":"414-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actualizaci\u00f3n sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posici\u00f3n y recomendaci\u00f3n en M\u00e9xico"],"prefix":"10.1016","volume":"83","author":[{"given":"A.","family":"Mayoral-Zavala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Esquivel-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"del Real-Calzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Guti\u00e9rrez-Grobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ramos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Rocha-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Rojas-Illanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Rubio-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"S\u00e1nchez-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.K.","family":"Yamamoto-Furusho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmx.2018.03.003_bib0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphar.2017.00419","article-title":"Sophisticated cloning, fermentation, and purification technologies for an enhanced therapeutic protein production: A review","volume":"8","author":"Gupta","year":"2017","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0220","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1734-1140(13)71466-X","article-title":"Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins","volume":"65","author":"Stryjewska","year":"2013","journal-title":"Pharmacol Rep."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int J Immunopathol Pharmacol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0230","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.12477","article-title":"Review article: Biosimilars are the next generation of drugs for liver and gastrointestinal diseases","volume":"38","author":"Rinaudo Gaujous","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0235","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/DDDT.S109852","article-title":"CT-P13: Design, development, and place in therapy","volume":"11","author":"Gabbani","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0240","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0245","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0250","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: Facts and fears of extrapolation","volume":"14","author":"Ben-Horin","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0255","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0260","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/00365521.2017.1369561","article-title":"Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients","volume":"52","author":"Eberl","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0265","first-page":"1325","article-title":"Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis-experiences from a single center","volume":"17","author":"Farkas","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0270","first-page":"3117","volume":"62","author":"Smits","year":"2017","journal-title":"Long-term clinical outcomes after switching from Remicade\u00ae to biosimilar CT-P13 in inflammatory bowel disease."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0275","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/jgh.12997","article-title":"Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study","volume":"30","author":"Jung","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2018.03.003_bib0280","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s10620-017-4511-4","article-title":"Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months","volume":"62","author":"Arg\u00fcelles Arias","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2018.03.003_bib0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","article-title":"Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea","volume":"9","author":"Park","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","article-title":"The PROSIT-BIO cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar","volume":"23","author":"Fiorino","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0295","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.gastrohep.2017.07.005","article-title":"Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission","volume":"40","author":"Guerrero Puente","year":"2017","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J Croh\u0144s Colitis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0305","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: The efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0310","unstructured":"Ley General de Salud, art. 222 bis, t\u00edtulo xii: Control sanitario de productos y servicios y de su importaci\u00f3n y exportaci\u00f3n. Cap\u00edtulo iv: Medicamentos."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0315","unstructured":"NORMA Oficial Mexicana NOM-257-SSA1-2014, en materia de medicamentos biotecnol\u00f3gicos."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0320","unstructured":"NORMA Oficial Mexicana NOM-177-SSA1-2013, que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0325","unstructured":"NORMA Oficial Mexicana NOM-220-SSA1-2016, instalaci\u00f3n y operaci\u00f3n de la farmacovigilancia."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","article-title":"Interchangeability of biosimilars: A European perspective","volume":"31","author":"Kurki","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yrtph.2015.12.013","article-title":"Biosimilars: A consideration of the regulations in the United States and European Union","volume":"76","author":"Daller","year":"2016","journal-title":"Regul Toxicol Pharmacol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0340","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Guidance for industry. Food and Drug Administration; 2017."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0345","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","article-title":"The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis","volume":"16","author":"Pecoraro","year":"2017","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0350","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/biot.201200065","article-title":"Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins","volume":"7","author":"Van Beers","year":"2012","journal-title":"Biotechnol J."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0355","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: Antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima","volume":"65","author":"Ben Horin","year":"2016","journal-title":"Gut."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0360","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0365","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0370","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14740338.2017.1323330","article-title":"Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: Results from Central European nationwide cohort","volume":"16","author":"B\u00e1lint","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rgmx.2018.03.003_bib0375","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-017-0693-5","article-title":"Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: A practical overview","volume":"77","author":"Hindryckx","year":"2017","journal-title":"Drugs."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0380","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/11538330-000000000-00000","article-title":"Mapping the safety profile of biologicals: A disproportionality analysis using the WHO adverse drug reaction database VigiBase","volume":"33","author":"Giezen","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0385","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0390","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0395","unstructured":"Ley General de Salud. Reglamento de insumos para la salud, t\u00edtulo sexto: autorizaciones y avisos. Cap\u00edtulo III: Registros. Art. 177 bis-2, bis-5."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11938-017-0122-6","article-title":"Extrapolation and interchangeability of infliximab and adalimumab in inflammatory bowel disease","volume":"15","author":"Chang","year":"2017","journal-title":"Curr Treat Options Gastroenterol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0405","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1517\/14712598.2015.1083552","article-title":"Biosimilar monoclonal antibodies: The scientific basis for extrapolation","volume":"15","author":"Schellekens","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0410","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17512433.2017.1283983","article-title":"Biosimilars in inflammatory bowel disease-accumulating clinical evidence","volume":"10","author":"McConachie","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0415","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: Facts and fears of extrapolation","volume":"14","author":"Ben Horin","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.rgmx.2018.03.003_bib0420","doi-asserted-by":"crossref","first-page":"772","DOI":"10.20452\/pamw.3550","article-title":"Update on the mechanisms of action of anti-TNF-\u03b1 antibodies and their clinical implications in inflammatory bowel disease","volume":"126","author":"Eder","year":"2016","journal-title":"Pol Arch Med Wewn."}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090618300831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090618300831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:02:58Z","timestamp":1751576578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0375090618300831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0375090618300831"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmx.2018.03.003","relation":{},"ISSN":["0375-0906"],"issn-type":[{"type":"print","value":"0375-0906"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posici\u00f3n y recomendaci\u00f3n en M\u00e9xico","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}